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Abstract
Objective: The aims of this study were to determine the clinical success rates, effect of neutropenia on treatment 
success rates, risk factors related to mortality, and survival in patients who developed hospital-acquired pneumonia 
(HAP) while receiving immunosuppressive therapy.
Materials and Methods: Forty-three adult patients receiving immunosuppressive therapy who developed HAP were 
included in this prospective study. Transplantation patients and human immunodeficiency virus (HIV)-positive 
patients were not included. Antibiotic treatment was managed by a multidisciplinary team. The Kaplan Meier 
method was used for the survival analysis and Cox regression was used for the identification of mortality-related 
independent risk factors. The relationship between neutropenia and the clinical success rate was determined using 
the chi-square test.  
Results: Although anti-pseudomonal antibiotics were started empirically in 40 of the 43 patients (93%) at the 
beginning of the treatment, the most frequently isolated pathogens were Acinetobacter spp. and Escherichia coli. 
The success rate at the end of the treatment was 65.1%. The survival rates for the 3rd, 14th, 42nd, and 365th days 
were 97%, 86%, 58%, and 19%, respectively. Elevated levels of urea [Hazard Ratio=1.01 (95% CI: 1.00–1.02)] and 
blood glucose [HR=1.01 (95% CI: 1.00–1.02)] were found to be independent risk factors affecting survival. The 
treatment success rate was higher in patients without neutropenia (n=23) than in those with neutropenia (n=20) 
(p=0.05). 
Conclusion: The treatment success rate was low in patients who developed HAP while receiving immunosuppressive 
therapy. (Turk J Hematol 2010; 27: 20-4)
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Özet
Amaç: ÇalÕýmamÕzda immunsupresif tedavi alÕrken hastane kökenli pnömoni (HKP) geliýen hastalarda klinik baýarÕ 
oranlarÕnÕ, nötropeninin tedavi baýarÕsÕna olan etkilerini, mortalite ile iliýkili risk faktörlerini ve survi oranlarÕnÕ saptamayÕ 
amaçladÕk. Introduction
In spite of prophylactic measures and the use of wide-
spectrum antibiotics, hospital-acquired pneumonia (HAP) is 
still an important cause of morbidity and mortality in patients 
receiving immunosuppressive therapy [1]. 
Algorithms for empirical antimicrobial treatment for sus-
pected pathogens have been developed for some immuno-
suppressed patient groups. The principle of empirical treat-
ment is based on an anti-pseudomonal approach, and in 
cases where there is no response and no pathogen is detect-
ed, treatment aimed at Aspergillus spp. or methicillin-resistant 
Staphylococcus aureus (MRSA) should be initiated. Invasive 
methods are only recommended in patients who do not 
respond to the initial antimicrobial treatment. Despite these 
structured empirical antimicrobial treatments using algorithms 
and the many invasive and non-invasive methods for pathogen 
isolation in these patients, mortality rates remain high. 
The aims of this study were to determine the clinical suc-
cess rates, effect of neutropenia on treatment success rates, 
risk factors related to mortality, and survival in patients who 
developed HAP while receiving immunosuppressive therapy.
Materials and Methods 
Adult patients who developed HAP while receiving immu-
nosuppressive therapy for solid organ tumors and hematologi-
cal malignancies at the Trakya Universty Medical Faculty 
Hospital between March 2005 and February 2006 were includ-
ed in this prospective study. 
a) Patients who were known to have no previous pneumo-
nia history and whose chest X-rays showed new infiltration at 
least 48 hours after hospital admission (that could not be 
explained otherwise) were diagnosed as HAP if one of the fol-
lowing criteria was present [2]:
• Fever (> 38°C) or hypothermia ( 36°C)
• Clinical findings such as dyspnea, coughing, new-
onset purulent sputum, or a change in the characteristics 
of the sputum
• Leukocytosis, leukopenia, and/or elevated C-reactive protein 
(CRP) (not associated with primary diseases and drug therapy)
• Consolidation findings on the physical examination
• Pathogen isolation in blood culture and/or sputum/trans-
tracheal aspirates 
b) In the presence of one or more of the following criteria, 
patients were diagnosed as having severe HAP [2]:
• Arterial oxygen pressure (PaO2)/fraction of inspired oxy-
gen (FiO2) <250
• Severe sepsis or signs of septic shock
• Bilateral or multilobar involvement, cavitation, abscess or 
effusion 
c) Pneumonias that developed >4 days after hospitalization 
were classified as “late pneumonia” [2]. 
d) Neutropenia was defined as either a neutrophil count of 
<500/mm3 or a neutrophil count of <1000/mm3 that would be 
expected to decrease [2]. 
Patients with fever and neutropenia but without new infiltra-
tion in the chest X-ray were excluded from the study. 
Study Protocol
Patients included in the study were evaluated prospectively. 
At the planning stage of the study, approval from the local eth-
ics committee was obtained, and each patient (or his/her 
caregivers) gave informed consent prior to participation in the 
study. Patients who had had consultations with a pulmonary 
medicine or infectious disease specialist and who were sus-
pected of having developed HAP according to the above crite-
ria while receiving immunosuppressive therapy were included 
in this study. 
Demographic data, risk factors, and the date of pneumonia 
development were recorded. Chest X-rays, complete blood 
counts, biochemistry parameters, arterial blood gases, CRP 
levels, and cultures of blood, sputum, or tracheal aspirate were 
studied prior to treatment, and pleural fluid was examined in 
patients with pleural effusion. The etiologic diagnostic criteria 
were defined as follows: by isolation of a microorganism in 
blood cultures or pleural fluid or with isolation of adequate 
sputum/tracheal samples in a pure or predominant culture, 
which correlated with the predominant morphology in the gram 
stain. Computerized tomography scans of the thorax were 
performed when indicated, and if the pathogen could not be 
isolated, empiric anti-pseudomonal treatment was initiated in 
line with national and international guidelines [2,3]. All patients 
were re-evaluated after 3-5 days to determine the success of 
the empirical treatment. If the pathogen was isolated, specific 
antibiotic treatment was initiated. When necessary, the treat-
ment regimen was redesigned in patients receiving empirical 
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Alternative empirical treatment was given to patients who 
showed no response to the initial empirical antibiotic treatment 
and in patients in whom the pathogen could not be isolated. 
Bronchoscopy and bronchial lavage were performed when 
required, and all of the patients were evaluated by a team of 
physicians from pulmonary and infectious disease specialties, 
as well as by the physicians responsible for the patient. 
Patients showing clinical improvement after treatment were 
discharged home and reassessed after six weeks. The follow-
up period was one year and all patients were contacted by 
telephone at the end of the year to determine their survival 
status. In the case of death, the date of death was recorded.
Statistics
Statistical analyses were conducted using the SPSS 9.0 
(SPSS Inc.; Chicago, IL, USA) statistical software, and descrip-
tive statistics and frequency analysis were performed. The 
Kaplan-Meier analysis was used for the analysis of survival. 
Factors that may have independently affected mortality were 
assessed using the univariate Cox regression analysis, and 
after the univariate analysis, the variables with a p value of <0.1 
were analyzed using a multivariate Cox regression model. The 
level of significance was set as p<0.05. The relationship 
between neutropenia and the clinical success rate was studied 
using the chi-square test. 
Results
A total of 43 patients [15 females (34.9%), 28 males 
(65.1%)] were included in the study. The mean age was 56.58 
± 15.31 years (range: 17-95 years). Severe pneumonia was 
observed in 27 patients (62.8%) and late pneumonia in 40 
patients (93%); the mean number of days before the develop-
ment of pneumonia was 24.8±20.2. Of the patients, 27 were 
receiving immunosuppressive therapy for hematological malig-
nancy (14 patients had acute myeloid leukemia, 7 multiple 
myeloma, 4 non-Hodgkin’s lymphoma, 1 myelodysplastic syn-
drome, and 1 mycosis fungoides) and 16 for solid tumors (9 
patients had lung cancer, 3 colon cancer, 2 stomach cancer, 
1 breast cancer, and 1 nasopharyngeal cancer). Twenty 
patients were neutropenic and 23 were non-neutropenic at the 
time of diagnosis. All the patients were considered to be high-
risk patients because they were receiving immunosuppressive 
therapy and had pneumonia. 
 The most commonly observed patient-related risk factors 
were hypoalbuminemia (93%), smoking (46.5%) and advanced 
age (27.9%) (Table 1).
Of the patients, 42 (97.6%) were given empirical treatment 
whilst the other patients underwent specific treatment, as the 
pathogen was isolated before the initiation of treatment. One 
patient had Acinetobacter spp. and was given cefepime in 
addition to an aminoglycoside. 
One non-neutropenic patient who developed HAP early (4 
days) was suspected of having HAP due to aspiration, and was 
therefore started on parenteral ampicillin-sulbactam. The other 
patient had a suspected atypical pathogen and was given cef-
triaxone plus clarithromycin. 
Of the 43 patients, 40 were started on empirical anti-pseu-
domonal treatment (ceftazidime plus aminoglycoside: n=13; 
ceftazidime plus ciprofloxacin: n=2; piperacillin/tazobactam 
plus aminoglycoside: n=6; piperacillin/tazobactam plus cipro-
floxacin: n=5; carbapenem plus aminoglycoside: n=14).   
The pathogen was isolated in 16 (37.2%) of the 43 patients. 
Three patients had 2 pathogens, and 1 patient had 3 patho-
gens. The most commonly isolated pathogens were 
Acinetobacter spp. (n=4), Escherichia coli (n=3), Streptococcus 
pneumoniae (n=2), Klebsiella spp. (n=2), Serratia spp. (n=2), 
Aspergillus fumigatus (n=2), MRSA (n=1), Streptococcus viri-
dans (n=1), Staphylococcus epidermidis  (n=1), Proteus spp. 
(n=1), Stenotrophomonas maltophilia (n=1), and Candida spp. 
(n=1). Twenty-one pathogens were isolated from 16 patients. 
Blood culture was positive in 4, sputum/aspirate culture was 
positive in 10, pleural samples were positive in 5, and bron-
choalveolar lavage culture was positive in 2. In 12 patients, the 
pathogens were isolated before the initiation of empirical treat-
ment. Six of these 12 patients had pathogens that were sensi-
tive to the empirical treatment and the treatment regimen was 
not changed, whereas the regimen was changed in the other 
6 patients. In 3 patients in whom the pathogen could not be 
isolated before initiation of the empirical antibiotic treatment, 
the pathogen was isolated at a later time. Glycopeptides (tei-
coplanin) were started in 6 patients and antifungal therapy was 
started in line with guidelines in 12 patients (amphotericin B: 
n=9; liposomal amphotericin B: n=2; Caspofungin: n=1) who 
were not responding to the initial antibiotic treatment [3]. 
Clinical success at the end of the treatment was achieved 
in 28 (65.1%) patients and clinical success at the end of the 
sixth week (follow success) was achieved in 24 (55.8%) 
patients. Four patients with clinical success at the end of treat-
ment died due to the primary disease at the end of the follow-
up period, and the pneumonia relapsed in 1 patient.
When the 16 patients with isolated pathogens and the 27 
patients with non-isolated pathogens were compared, the dif-
ference in the rates of clinical success at the end of treatment 
was significant (p=0.024). The difference between the clinical 
success rates at the end of the follow-up period was also sig-
nificant (p=0.013). The success rate was higher in patients in 
whom the pathogen could not be isolated. 
When the 20 neutropenic and 23 non-neutropenic patients 
were compared, the difference in the rates of clinical success at 
Table 1. Patient-related risk factors
Risk factors related to patients  N  %
Hypoalbuminemia (< 3.5 mg/dl)  40  93
Smoking 20  46.5
Age >65   12  27.9
Alcohol     8  18.6
COPD    4  9.3
CVD    4  9.3
Diabetes    3  7.0
CRF    2  4.7
COPD: Chronic obstructive  pulmonary disease; CVD: Cerebrovascular disease; CRF: 
Chronic renal failure
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ference between the clinical success rates at the end of the 
follow-up period was not significant. The success rate at the end 
of treatment was higher in patients who were not neutropenic. 
Eighteen (42%) of the 43 patients had died by the end of 
the six-week follow-up period. According to the Kaplan Meier 
survival analysis, the survival rates for the 3rd, 14th, 42nd, and 
365th days were 97%, 86%, 58%, and 19%, respectively. 
There were no significant differences between living and 
exitus patients in terms of age, gender, the mean number of 
days before the development of pneumonia, severe pneumonia, 
hypotension, comorbid status, medical treatment, or radiology.
Three patients suffered from pneumonia attacks in the 
study year while they were in the hospital for the second time 
to receive immunosuppressive therapy. Two patients devel-
oped community-acquired pneumonia, and 11% of the patients 
developed recurrent pneumonia during the year. 
The effect of risk factors on survival was studied using uni-
variate Cox regression analysis. Urea and fasting blood glucose 
(FBG) were found to be p<0.1 and were re-analyzed using mul-
tivariate analysis; urea (p=0.012) and FBG (p=0.004) were 
found to be the independent factors affecting survival. Elevated 
levels of urea [hazard ratio (HR) (95% confidence interval): 1.01 
(1.00-1.02)] and FBG [HR (95%CI): 1.01 (1.00-1.02)] were the 
independent risk factors adversely affecting survival. 
Discussion 
Due to the widespread use of immunosuppressive therapies, 
hospital-acquired infections in patients receiving immunosup-
pressive therapy are an important problem for today’s clinicians. 
The most common pathogen found in our study was 
Acinetobacter spp., followed by E. coli. The most common 
pathogen responsible for HAP in our previous study (which 
included patients receiving immunosuppressive therapy and 
others as well) was also Acinetobacter spp. [4]. In another 
study, Pseudomonas spp. was the most common pathogen in 
patients receiving immunosuppressive therapy who developed 
HAP; therefore, they are a target for empirical treatment, espe-
cially in neutropenic patients [5]. However, Pseudomonas spp. 
were not isolated in our study. Fungal pathogens, in particular 
Aspergillus spp., were responsible for the HAP in patients with 
hematological malignancies, and they contributed to a high 
mortality rate [6]. In patients with a hematological malignancy, 
the rate of definitive Aspergillus spp. was 5-6% [7]. Aspergillus 
spp. was isolated in two patients (4%), and this rate was con-
sistent with the literature. 
The treatment success rate was low and the mortality rate 
high in patients receiving immunosuppressive therapy who 
developed HAP [8]. We found the clinical success rates at the 
end of the treatment and at the end of the follow-up period to 
be 65% and 56%, respectively. In a study comparing the HAP 
of 20 immunocompetent patients with that of 54 immunocom-
promised patients, the mortality rates were found to be high in 
both groups (60% and 50%, respectively) [9]. 
There are many comparative studies on pathogen isolation 
in patients receiving immunosuppressive therapy [10]. However, 
despite the widespread use of non-invasive and/or broncho-
scopic methods to isolate pathogens, we could not find any 
studies in the literature on the relationship between pathogen 
isolation and clinical success rates in these patients [except the 
studies involving transplantation and human immunodeficiency 
virus (HIV)].
In our study, the success rate of the group in which the 
pathogen could not be isolated was higher than that of the 
group in which the pathogen was isolated (there were no sig-
nificant differences between the groups in terms of age, gen-
der, comorbid status, or APACHE II scores). 
It is difficult to explain this fact. Are the microorganisms 
responsible for pneumonia in patients with higher clinical suc-
cess rates the ones that are difficult to isolate? Are the patient-
related factors more important than the pathogen-related fac-
tors in clinical success? We think that larger studies should be 
conducted to answer these questions. However, the higher 
treatment success rates in non-neutropenic patients than in 
neutropenic patients may be considered a finding that sup-
ports the importance of patient-related factors. 
According to the Kaplan Meier survival analysis, the sur-
vival rates for the 3rd, 14th, 42nd, and 365th days were 97%, 
86%, 58%, and 19%, respectively. We could not find any other 
study in the literature with such a long follow-up period. The 
reason for the low one-year survival rates may be the progres-
sive characteristics of the underlying disease in these patients 
and the toxic and immunosuppressive characteristics of the 
medications they were receiving. Although the one-year sur-
vival rates were low, 11% of the patients had recurrent pneu-
monia, which indicates the high susceptibility of these patients 
to serious infections. 
We found elevated urea and FBG levels to be the inde-
pendent risk factors that negatively affected survival. These 
results show that it is necessary not only to choose the 
antimicrobial drugs in HAP treatment, but also to address 
the metabolic problems. Notably, the limitation of our study 
with respect to the small number of patients may have pre-
vented us from finding other independent risk factors. 
Elevated urea and FBG levels have been reported in com-
munity-acquired pneumonia [11], but we could not find any 
studies in the literature on the factors affecting the survival 
of patients receiving immunosuppressive therapy who 
developed HAP. 
In conclusion, the treatment success rate was low in 
patients who developed HAP while receiving immunosuppres-
sive therapy. 
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